燃爆ASCO!默沙东打出ADC“王炸”,来自中国

E药经理人
04 Jun

ADC进击大战,在肿瘤学领域最重要的盛事——美国临床肿瘤学会(ASCO)年会上,彻底洗牌。过往,Seagen、ImmunoGen和Spirogen三大技术先驱把握ADC“要塞”,而阿斯利康、罗氏、辉瑞等作为MNC“摘果者”,长驱直入、抓住要害,奠定地位。自2020年起,ADC排位赛格局被全力布局的默沙东打破。相较数年前专注于“K药策略+免疫治疗+晚期疾病突破”的战略,如今的默沙东,正致力于打造一个...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10